surmount-1 trial tirzepatide non-diabetic obesity weight loss for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - SURMOUNT-1: Tirzepatide Drastically Reduces Weight
Description
Individuals with inflammatory bowel disease, gastroparesis, or other gastrointestinal disorders require special consideration for tirzepatide dosing for weight loss in units
Blood glucose monitoring is essential, particularly for patients on insulin or sulfonylureas, during tirzepatide initiation and dose escalation
The first step a patient takes is receiving a prescription from their healthcare provider
& Yasuda, S
However, the manufacturing process, purity testing, and quality controls differ between a compounding pharmacy and a major pharmaceutical manufacturer
